TLDR
- Tempus AI stock rose as much as 10.67%, trading at $64.63 after Piper Sandler upgraded the stock to Overweight with a $76 price target.
- The upgrade was driven by optimism around the Personalis acquisition and encouraging clinical data.
- TEM beat Q2 earnings, reporting a $0.04 adjusted loss per share versus the expected $0.14 loss, with revenue up 21.6% year-over-year to $382.49 million.
- New catalysts include a $9.5 million federal grant for cardiology AI and a large whole-genome dataset initiative.
- The consensus analyst rating remains Hold with an average price target of $69.33, though several firms have raised their targets recently.
Tempus AI (TEM) stock climbed as much as 10.67% on September 15, with the stock trading at $64.63 during mid-day trading, up from a prior close of $62.21. The intraday high reached $65.50.
The main driver was a fresh upgrade from Piper Sandler, which moved TEM to Overweight and set a price target of $76. The firm pointed to optimism around Tempus’s acquisition of Personalis and positive clinical data as key reasons for the call.
CEO Eric Lefkofsky added to the bullish tone at a recent conference, highlighting revenue upside from higher pricing on the company’s liquid biopsy services.
Earnings Beat Adds to the Momentum
Tempus recently posted better-than-expected quarterly results. The company reported an adjusted loss of $0.04 per share, well ahead of the consensus estimate of a $0.14 loss.
Revenue came in at $382.49 million for the quarter, just above analyst expectations of $379.69 million. That represented 21.6% growth compared to the same period last year.
Despite the strong top-line performance, Tempus remains unprofitable. The company posted a negative net margin of 17.77% and a negative return on equity of 50.28%.
Fresh Catalysts in Focus
Beyond the upgrade, investors are watching two new developments. Tempus received a $9.5 million federal grant to support its cardiology AI work.
The company also launched a large whole-genome dataset initiative, aimed at expanding its AI-driven tools and deepening its data platform. Both moves reflect Tempus’s push to grow its footprint with clinicians and biopharma partners.
Guggenheim raised its price target from $60 to $65, giving TEM a Buy rating. Needham maintained its Buy rating with a $75 price target. HC Wainwright lifted its target from $56 to $66.
The current consensus analyst rating sits at Hold, with an average price target of $69.33 across 21 analysts. Of those, 11 have a Buy, eight a Hold, and two a Sell rating.
Institutional interest has been growing. Sumitomo Mitsui Trust Group raised its stake by 23.4% in Q1, while Franklin Resources lifted its position by 27.9% in Q4. Institutional investors now own 24.22% of the stock.
On the insider side, EVP Andrew Polovin sold 7,927 stock units at $56.00 on August 19, and CEO Ryan Fukushima sold 14,286 units at $70.00 on August 21. Over the last 90 days, insiders have sold stock valued at approximately $56.96 million.
The stock’s 50-day moving average stands at $55.99, and its 200-day moving average is $52.33. TEM carries a debt-to-equity ratio of 3.06 and a beta of 3.72, reflecting its high volatility profile.
Tempus’s market cap stands at approximately $10.65 billion as of September 15.
Stop guessing and start investing with confidence. KnockoutStocks gives you the AI insights, market intelligence, and stock research you need to spot opportunities, cut through the noise, and make smarter investment decisions — all in one powerful platform.
Sign up today and get 50% OFF full access to our premium stock picks.
Simply use coupon code SPECIAL50 at checkout to claim your exclusive discount.
Be the first to comment